Free Trial
NASDAQ:NBIX

Neurocrine Biosciences Q1 2025 Earnings Report

Neurocrine Biosciences logo
$109.68 +3.09 (+2.90%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$109.15 -0.53 (-0.48%)
As of 05/2/2025 04:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Neurocrine Biosciences EPS Results

Actual EPS
N/A
Consensus EPS
$0.70
Beat/Miss
N/A
One Year Ago EPS
N/A

Neurocrine Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
$587.06 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Neurocrine Biosciences Announcement Details

Quarter
Q1 2025
Time
After Market Closes
Conference Call Date
Monday, May 5, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

Neurocrine Biosciences Earnings Headlines

Elon’s Terrifying Warning Forces Trump To Take Action
Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of collapse and built two of the most valuable companies in history. Now, he's sounding the alarm about America's $36 trillion debt time bomb that could destroy the fabric of our society.As head of the Department of Government Efficiency (DOGE) under President Trump, Musk is exposing just how bad things are...
See More Neurocrine Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Neurocrine Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Neurocrine Biosciences and other key companies, straight to your email.

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ:NBIX) discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

View Neurocrine Biosciences Profile

More Earnings Resources from MarketBeat